Novo Faces Setback on New Product Launch Due to FDA Restrictions

Celltrion’s U.S. Plant Awaits Key Approval for Manufacturing Site Addition

OAI Track Record Prior to Acquisition Emerges as a Factor During FDA Inspection

Attempts by Novo Nordisk to secure a U.S. manufacturing base by acquiring an entire local plant have run into regulatory barriers. This is due to the company’s failure to obtain additional local approval for the production of new products. Since Celltrion also acquired a U.S. plant late last year to begin manufacturing its own products in a similar manner, there is growing analysis that the key issue will be how smoothly it can overcome regulatory hurdles, such as applications to add new manufacturing sites.


According to the global bio industry and other sources on the 12th, American biotechnology company Scholar Rock recently resubmitted a Biologics License Application (BLA) for its spinal muscular atrophy drug candidate, apitegromab, to the U.S. Food and Drug Administration (FDA), but excluded the former Catalent plant now owned by Novo from its contract manufacturers.


The Catalent plant, which Novo acquired in 2024 to establish a U.S. production base, is a finished drug manufacturing facility. However, it received an Official Action Indicated (OAI)—the FDA’s most severe enforcement status—last year. After another inspection in April of this year, it was issued a second OAI. As a result, even after 1 year and 8 months since the acquisition, the facility remains hamstrung by regulatory roadblocks and is unable to function as intended.

A view of the Celltrion production facility located in Branchburg, New Jersey, USA. Celltrion

A view of the Celltrion production facility located in Branchburg, New Jersey, USA. Celltrion

View original image

This naturally shifts attention to Celltrion. The local U.S. plant Celltrion acquired to establish its own production base must also pass similar inspections. In December 2025, Celltrion purchased Eli Lilly’s drug substance (DS) manufacturing plant in Branchburg, New Jersey, for $330 million (approximately 467 billion won). Currently, under a contract manufacturing organization (CMO) agreement with Lilly, Celltrion is manufacturing Lilly’s products at the site and recorded 50 billion won in sales during the second quarter.


Celltrion’s larger purpose in acquiring this facility is to begin manufacturing its own pipeline products. To do so, Celltrion must submit a supplemental Biologics License Application (sBLA) to add the Branchburg plant as a manufacturing site for relevant products and then undergo a pre-approval inspection (PAI) by the FDA. Novo’s Catalent facility likewise received a Complete Response Letter (CRL) from the FDA at the plant addition review stage.


Celltrion Plant Also Faces 'FDA OAI History' as a Variable


The Branchburg plant acquired by Celltrion also has a regulatory inspection history. According to FDA facility inspection records reviewed as of the 12th, the Branchburg plant was hit with two OAIs by the FDA in 2019 and 2020, when it was operated by Eli Lilly. In the most recent inspection in 2022, the severity was reduced to a Voluntary Action Indicated (VAI), but it is analyzed that facilities which received prior corrective actions are subject to even stricter pre-approval inspections. This may serve as a variable in the upcoming site registration process.


Moreover, since Branchburg is a DS (drug substance) plant, converting the site for full-scale manufacturing is considered even more challenging compared to a finished product plant like Catalent’s. Whenever there is a change in the raw material production process, a new comparability assessment is required to prove that the same product substance is being manufactured.



Celltrion is aiming to avoid repeating Novo’s mistakes and has spent more than six months preparing for the approval process, with the goal of beginning in-house product manufacturing at the plant next year as planned. The company is said to be focusing its capabilities on eliminating procedural uncertainties in advance by leveraging its local network and other resources. A Celltrion official stated, “We are currently carrying out technology transfer and validation, and we plan to sequentially submit sBLAs to add manufacturing sites for products as soon as data preparation is complete.” It typically takes anywhere from six months to more than a year to receive approval after submitting a site change application and undergoing inspection.

Will Celltrion Avoid Novo Nordisk’s ‘Idle U.S. Plant’ Pitfall? Proceeding with Caution View original image

The situation for other major bio companies with U.S. manufacturing plants is somewhat different. Unlike Celltrion, which must pass the hurdle of site registration since its primary goal is manufacturing its own products, Samsung Biologics (Rockville, Maryland, formerly GSK plant) and Lotte Biologics (Syracuse, New York, formerly BMS plant) are focused on contract manufacturing existing client pharmaceuticals. Therefore, they can continue to use their current production systems as they are.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing